探索Pseuderanthemum crenulatum的抗高血糖潜力:隔离,结构阐明和α-葡萄糖酶抑制评估
Dung V Ngo1,2, Le-Thu T Nguyen1,2, Ngoc T N Ngo1,2
1Faculty of Chemistry, VNUHCM-University of Science, 227 Nguyen Van Cu Street, District 5, Ho Chi Minh City, 700000, Vietnam.
Journal of natural medicines
|April 23, 2025
概括
伪白 (Pseuderanthemum crenulatum) 的化合物通过抑制α-葡萄糖酶,表现出强烈的抗糖尿病活性. 化合物9是最有效的,为糖尿病管理研究提供了新的途径.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 传统上,Pseuderanthemum crenulatum被用于糖尿病管理.
- 在P.crenulatum的化学成分和抗糖尿病潜力基本上没有特征.
研究的目的:
- 从P.crenulatum的茎和根中分离和描述化学化合物.
- 通过评估它们的α-葡萄糖酶抑制作用来评估分离化合物的抗高糖活性.
主要方法:
- 柱状染色法用于化合物隔离.
- 用1D和2DNMR实验进行结构阐明.
- 通过α-葡萄糖酶抑制试验评估了体外抗高血糖活性.
主要成果:
- 他们分离出了一种新的阿比类型的迪诺迪特,伪胺 (1),以及十种已知的化合物 (2-11).
- 化合物1-3和6-10表现出显著的α-葡萄糖酶抑制,超过了阳性对照,阿卡尔.
- 化合物9显示出最强大的抑制活性 (IC50几乎是阿卡尔的10倍).
- 动力学研究显示混合型 (化合物2),非竞争性 (化合物3) 和其他化合物的竞争性抑制.
结论:
- P.crenulatum是一种有价值的化合物来源,具有显著的抗糖尿病潜力.
- 伪丹西蒙和其他分离化合物显示出有前途的α-葡萄糖酶抑制活性.
- 对这些化合物的进一步研究可能会导致新的糖尿病治疗方法.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
105
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
105
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250


